XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Balance Sheet Account Detail
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Account Detail BALANCE SHEET ACCOUNT DETAIL
The composition of selected financial statement captions that comprise the accompanying Condensed Consolidated Balance Sheets are summarized below:
(a) Cash and Cash Equivalents and Marketable Securities
We maintain cash balances with select major financial institutions. The Federal Deposit Insurance Corporation (FDIC) and other third parties insure a fraction of these deposits. Accordingly, these cash deposits are not insured against the possibility of a substantial or complete loss of principal and are inherently subject to the credit risk of the corresponding financial institution.
Our investment policy requires that purchased investments may only be in highly-rated and liquid financial instruments and limits our holdings of any single issuer (excluding any debt or equity securities that may be received from our strategic partners in connection with an out-license arrangement).
The carrying amount of our equity securities, money market funds, and bank CDs approximates their fair value (utilizing “Level 1” or “Level 2” inputs) because of our ability to immediately convert these instruments into cash with minimal expected change in value. As of September 30, 2020, our held securities that remain in an unrealized loss position for less than one year were insignificant and are presented in the table below.
The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:
Historical or Amortized CostForeign Currency TranslationUnrealized
Gains		Unrealized
Losses		Fair
Value		Cash and Cash
Equivalents		Marketable Securities
September 30, 2020
Money market funds$59,923 $— $— $— $59,923 $59,923 $— 
Equity securities5,008 (2,065)11,186 — 14,129 — 14,129 
Government-related debt securities90,232 — 105 — 90,337 7,499 82,838 
Corporate debt securities16,470 — 15 16,485 — 16,485 
Mutual funds3,925 — 628 — 4,553 — 4,553 
Bank CDs3,156 — 18 — 3,174 — 3,174 
Bank deposits9,710 — — — 9,710 9,710 — 
Total cash and cash equivalents and marketable securities$188,424 $(2,065)$11,952 $— $198,311 $77,132 $121,179 
December 31, 2019
Money market funds$54,199 $— $— $— $54,199 $54,199 $— 
Equity securities6,310 (2,477)27,214 — 31,047 — 31,047 
Government-related debt securities62,617 — 19 (10)62,626 — 62,626 
Corporate debt securities58,235 — 38 (25)58,248 5,000 53,248 
Mutual funds4,375 — 783 — 5,158 — 5,158 
Bank CDs7,354 — 22 — 7,376 — 7,376 
Bank deposits5,219 — — — 5,219 5,219 — 
Total cash and cash equivalents and marketable securities$198,309 $(2,477)$28,076 $(35)$223,873 $64,418 $159,455 
(b) Other Receivables

“Other receivables” consists of the following:
September 30, 2020December 31, 2019
Insurance receivable$74 $4,015 
CASI other receivables— 2,393 
Other miscellaneous receivables 1,393 1,490 
Income tax receivable - current portion 1,297 973 
Interest receivable from marketable securities293 561 
Reimbursements for incurred research and development expenses129 126 
Other receivables$3,186 $9,558 

(c) Prepaid Expenses and Other Current Assets
“Prepaid expenses and other current assets” consists of the following:
September 30, 2020December 31, 2019
Vendor deposits$10,804 $8,740 
Prepaid insurance72 1,408 
Prepaid expenses and other current assets$10,876 $10,148 

(d) Property and Equipment, net
“Property and equipment, net” consists of the following: 
September 30, 2020December 31, 2019
Manufacturing equipment$18,199 $10,355 
Computer hardware and software2,781 3,606 
Laboratory equipment36 36 
Leasehold improvements3,374 3,374 
Office furniture248 248 
Property and equipment, at cost24,638 17,619 
(Less): Accumulated depreciation(6,182)(6,012)
Property and equipment, net$18,456 $11,607 
Manufacturing equipment is comprised of our owned ROLONTIS production equipment on location at our contract manufacturer. This equipment has alternative future use for the general production of various biologic agents. Accordingly, we have capitalized these purchases, rather than recording it as “research and development” expense in full, despite its current designation for the manufacture of pre-FDA approved product. The majority of this manufacturing equipment was not in use and therefore not being depreciated as of September 30, 2020. Depreciation for installed and ready-for-use equipment is recorded to “research and development” expense prior to FDA approval and will be prospectively recorded to “cost of sales” upon FDA approval of ROLONTIS.
(e) Accounts Payable and Other Accrued Liabilities
“Accounts payable and other accrued liabilities” consists of the following:
September 30, 2020December 31, 2019
Trade accounts payable and other $32,047 $32,012 
Lease liability - current portion1,655 1,683 
Accrued commercial/Medicaid rebates2,122 2,925 
Accrued product royalty due to licensors— 66 
Allowance for product returns4,473 4,714 
Accrued data and distribution fees768 768 
Accrued GPO administrative fees6 6 
Accrued inventory management fees168 364 
Allowance for government chargebacks11,746 11,746 
Accounts payable and other accrued liabilities $52,985 $54,284 
Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates were as follows:
Commercial/Medicaid Rebates and Government ChargebacksDistribution, Data, Inventory and
GPO Administrative Fees		Product Return Allowances
Balance as of December 31, 2018$22,952 $3,932 $5,171 
Add: GTN accruals recorded for product sales 7,702 1,209 167 
(Less): Payments made and credits against GTN accruals (15,983)(4,003)(624)
Balance as of December 31, 2019$14,671 $1,138 $4,714 
Add: GTN accruals recorded for product sales— — — 
(Less): Payments made and credits against GTN accruals (803)(196)(241)
Balance as of September 30, 2020$13,868 $942 $4,473